Taiwan Regulators Plan Genetic Testing for Dangerous Side Effects of Anticonvulsant | GenomeWeb
NEW YORK (GenomeWeb News) – Taiwan’s Department of Health said this week that it has updated the label for the anticonvulsant drug carbamazapine to warn patients of a genetic link to potentially serious side effects, and said that it plans to test patients for adverse reactions to the drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.